MX365111B - Síntesis de copanlisib y su sal diclorhidrato. - Google Patents

Síntesis de copanlisib y su sal diclorhidrato.

Info

Publication number
MX365111B
MX365111B MX2017005891A MX2017005891A MX365111B MX 365111 B MX365111 B MX 365111B MX 2017005891 A MX2017005891 A MX 2017005891A MX 2017005891 A MX2017005891 A MX 2017005891A MX 365111 B MX365111 B MX 365111B
Authority
MX
Mexico
Prior art keywords
copanlisib
synthesis
dihydrochloride salt
intermediate compounds
dihydrochloride
Prior art date
Application number
MX2017005891A
Other languages
English (en)
Spanish (es)
Other versions
MX2017005891A (es
Inventor
Stiehl Jürgen
Lovis Kai
Georg Peters Jan-
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2017005891A publication Critical patent/MX2017005891A/es
Publication of MX365111B publication Critical patent/MX365111B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
MX2017005891A 2014-11-07 2015-11-05 Síntesis de copanlisib y su sal diclorhidrato. MX365111B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192202.1A EP3018131A1 (en) 2014-11-07 2014-11-07 Synthesis of copanlisib and its dihydrochloride salt
PCT/EP2015/075765 WO2016071426A1 (en) 2014-11-07 2015-11-05 Synthesis of copanlisib and its dihydrochloride salt

Publications (2)

Publication Number Publication Date
MX2017005891A MX2017005891A (es) 2017-06-30
MX365111B true MX365111B (es) 2019-05-23

Family

ID=51866060

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005891A MX365111B (es) 2014-11-07 2015-11-05 Síntesis de copanlisib y su sal diclorhidrato.

Country Status (34)

Country Link
US (1) US10035803B2 (und)
EP (2) EP3018131A1 (und)
JP (1) JP6691114B2 (und)
KR (1) KR102562286B1 (und)
CN (1) CN107074776B (und)
AR (1) AR102568A1 (und)
AU (1) AU2015341779B2 (und)
BR (1) BR112017009471B1 (und)
CA (1) CA2966796C (und)
CL (1) CL2017001130A1 (und)
CO (1) CO2017004533A2 (und)
DK (1) DK3215507T3 (und)
EA (1) EA031248B1 (und)
ES (1) ES2716730T3 (und)
HR (1) HRP20190527T8 (und)
HU (1) HUE042794T2 (und)
IL (1) IL251586B (und)
JO (1) JO3487B1 (und)
LT (1) LT3215507T (und)
MX (1) MX365111B (und)
MY (1) MY183123A (und)
NZ (1) NZ730843A (und)
PE (1) PE20170951A1 (und)
PL (1) PL3215507T3 (und)
PT (1) PT3215507T (und)
RS (1) RS58494B1 (und)
SG (1) SG11201702999XA (und)
SI (1) SI3215507T1 (und)
TR (1) TR201904346T4 (und)
TW (1) TWI697494B (und)
UA (1) UA118999C2 (und)
UY (1) UY36396A (und)
WO (1) WO2016071426A1 (und)
ZA (1) ZA201703866B (und)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
WO2014166820A1 (en) 2013-04-08 2014-10-16 Bayer Pharma Aktiengesllschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas
EP3018127A1 (en) * 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
CA2978830A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
CN105130998B (zh) * 2015-09-25 2017-07-28 苏州立新制药有限公司 库潘尼西的制备方法
WO2017153220A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2—amino—n— [7—methoxy—2, 3-dihydroimidazo-[1, 2-c] quinazolin-5-yl] pyrimidine—5—carboxamides
WO2018054782A1 (en) 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1319674B1 (it) * 2000-12-01 2003-10-23 Erregierre Spa Processo per la preparazione dell'acido1-(aminometil)cicloesanacetico.
TW565582B (en) * 2001-04-13 2003-12-11 Kaneka Corp Diamine, acid dianhydride, and reactive group containing polyimide composition prepared therefrom and preparing them
CN100506817C (zh) * 2001-08-15 2009-07-01 纳幕尔杜邦公司 用于防治无脊椎害虫的邻-杂环取代的芳基酰胺类化合物
MXPA05001808A (es) 2002-09-30 2005-08-16 Bayer Pharmaceuticals Corp Derivados de azol-pirimidina condensados.
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2244721A4 (en) * 2008-01-14 2017-01-18 Bayer Intellectual Property GmbH Sulfone substituted 2,3-dihydroimidazo ý1,2-c¨quinazoline derivatives useful for treating hyper-proliferative disorders and diseases with angiogenesis
AU2010317167B2 (en) 2009-11-04 2012-11-29 Novartis Ag Heterocyclic sulfonamide derivatives useful as MEK inhibitors
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts

Also Published As

Publication number Publication date
CA2966796C (en) 2022-12-06
US20170327505A1 (en) 2017-11-16
LT3215507T (lt) 2019-04-10
PE20170951A1 (es) 2017-07-13
CN107074776B (zh) 2021-02-02
JP2017536352A (ja) 2017-12-07
AU2015341779B2 (en) 2020-02-27
DK3215507T3 (en) 2019-04-15
EP3215507B1 (en) 2018-12-26
PT3215507T (pt) 2019-03-29
ES2716730T3 (es) 2019-06-14
KR20170078654A (ko) 2017-07-07
EA031248B1 (ru) 2018-12-28
HUE042794T2 (hu) 2019-07-29
TW201625633A (zh) 2016-07-16
RS58494B1 (sr) 2019-04-30
EA201790982A1 (ru) 2017-10-31
HRP20190527T8 (hr) 2020-02-21
BR112017009471A2 (pt) 2018-01-02
TR201904346T4 (tr) 2019-04-22
WO2016071426A1 (en) 2016-05-12
PL3215507T3 (pl) 2019-08-30
MY183123A (en) 2021-02-15
SI3215507T1 (sl) 2019-04-30
CL2017001130A1 (es) 2018-01-19
JP6691114B2 (ja) 2020-04-28
EP3018131A1 (en) 2016-05-11
IL251586B (en) 2019-05-30
IL251586A0 (en) 2017-06-29
JO3487B1 (ar) 2020-07-05
MX2017005891A (es) 2017-06-30
SG11201702999XA (en) 2017-05-30
CA2966796A1 (en) 2016-05-12
ZA201703866B (en) 2019-06-26
HRP20190527T1 (hr) 2019-05-17
AR102568A1 (es) 2017-03-08
KR102562286B1 (ko) 2023-08-02
UA118999C2 (uk) 2019-04-10
EP3215507A1 (en) 2017-09-13
US10035803B2 (en) 2018-07-31
BR112017009471B1 (pt) 2023-02-28
CO2017004533A2 (es) 2017-07-19
TWI697494B (zh) 2020-07-01
CN107074776A (zh) 2017-08-18
UY36396A (es) 2016-06-30
NZ730843A (en) 2022-12-23
AU2015341779A1 (en) 2017-05-11

Similar Documents

Publication Publication Date Title
PH12017500833A1 (en) Synthesis of copanlisib and its dihydrochloride salt
NZ765780A (en) 2-(morpholin-4-yl)-1,7-naphthyridines
JO3487B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
MX2020001278A (es) Sintesis de compuestos de carbamoilpiridona policiclica.
IN2014CH00247A (und)
JOP20170100B1 (ar) توليف مركبات إندازول
MX369357B (es) Procedimiento de compuesto antifungico.
MX365494B (es) Procedimiento de compuesto antifungico.
IN2014MU00455A (und)
MX2017011389A (es) Proceso para la preparacion de 3-cloro-2-vinilfenilsulfonatos.
MX2016015624A (es) Proceso para la preparacion de derivados de tiazol.
HRP20190286T1 (hr) Postupci za pripremu spojeva, kao što su 3-arilbutanali, korisni u sintezi medetomidina
ZA201803250B (en) New 5-azido-5-deoxy-2 :3-isopropylidene-d-arabinose compounds; their method of manufacture and their use for the synthesis of ara-n3, kdo-n3 and 4ekdo-n3
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.
MX2016015623A (es) Proceso para la preparacion de derivados dihidroisoxazol.
IN2014CH00444A (und)
IN2014MU00072A (und)
IN2013MU01501A (und)
MX2017011388A (es) Proceso para la preparacion de derivados de fenilisoxazolina sustituida.
IN2014MU00070A (und)
IN2014MU01191A (und)
TW201613927A (en) Method for preparation of substituted imidazopyridazines
IN2013MU01524A (und)

Legal Events

Date Code Title Description
FG Grant or registration